Apatinib
Apatinib
Apatinib (pronounced: a-pa-ti-nib), also known as YN968D1, is a small molecule inhibitor that selectively inhibits the vascular endothelial growth factor receptor 2 (VEGFR2), also known as KDR. It is an orally bioavailable, synthetic, small molecule antiangiogenic agent with potential antineoplastic activity.
Etymology
The term "Apatinib" is derived from the combination of "APA" (an abbreviation of anti-platelet-derived growth factor receptor), "tin" (indicating its inhibitory nature), and "ib" (a common suffix for small molecule inhibitors).
Mechanism of Action
Apatinib inhibits VEGFR2 which may result in the inhibition of tumor growth and angiogenesis, and thus metastasis. It has been used in trials studying the treatment of gastric cancer, colorectal cancer, and breast cancer.
Related Terms
- Angiogenesis: The physiological process through which new blood vessels form from pre-existing vessels.
- Antineoplastic: A substance that inhibits or prevents the growth and spread of tumors or malignant cells.
- Inhibitor: A substance that slows down or prevents a particular chemical reaction or other processes.
- Metastasis: The spread of a cancer or other disease from one organ or part to another not directly connected with it.
- VEGFR2: Vascular endothelial growth factor receptor 2, a protein that is encoded by the KDR gene in humans.
External links
- Medical encyclopedia article on Apatinib
- Wikipedia's article - Apatinib
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski